Phagenesis appoints chairman and ceo

Will lead the development of treatments for stroke victims

Phagenesis, a UK leader in technology for the treatment of stroke patients, has appointed Henry Hyde-Thomson as chairman and Daniel Green as chief executive. They will lead the University of Manchester spin out in the development of a new class of treatments for stroke victims suffering from dysphagia, a condition that prevents or impairs the safe swallowing of food and drink.

Phagenesis’ technology is a device that delivers electrical pulses to the throat region that can ‘awaken’ the brain to help restore swallowing function. At least 50% of stroke victims have impaired swallowing. Apart from a severe reduction in quality of life, dysphagia often leads to the inhalation of liquids and the development of life-threatening pneumonia.

Green was formerly chief executive of Repregen, an Imperial College spinout. Before that, he was a venture capital investor at HBM Partners in Zurich, Switzerland, Dresdner Kleinwort and MVM, in London, UK.

You may also like

Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Research & Development

iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases

The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development
Subscribe now